There is nothing one-off about the 1 October and 1 April changes because they are simply the first stage of a new pricing framework that represents a profound structural change in the PBS policy framework that no company or part of the sector will escape. …
No part of the sector will escape the impact of these structural changes
August 26, 2022 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
Nyrada commences recruitment for phase one clinical trial
March 17, 2025 - -
Neurizon Therapeutics updates investors on initiatives to lift clinical hold
March 17, 2025 - - Australian Biotech -
Radiopharm Theranostics says new data confirms positive tumour uptake
March 17, 2025 - - Australian Biotech -
Race secures ethics approval for RC220 Phase 1 solid tumour trial
March 17, 2025 - - Australian Biotech -
TGA approves Novartis therapy for most commonly diagnosed type of early breast cancer
March 17, 2025 - - Latest News -
Doctor group changes position on weight-loss therapies and the PBS
March 17, 2025 - - Latest News -
In 2025, the US is more likely to adopt PBS pricing policies than oppose them
March 17, 2025 - - Latest News